Circulating DNA Analysis for Soft Tissue Sarcoma
Trial Summary
What is the purpose of this trial?
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the idea that Circulating DNA Analysis for Soft Tissue Sarcoma is an effective treatment?
The available research shows that Circulating DNA Analysis can help monitor soft tissue sarcoma by detecting changes in tumor DNA found in the blood. This method allows doctors to track the disease without invasive procedures. For example, one study found that when patients were in full remission, no tumor DNA was detected, but it was present when the disease was active. This suggests that the treatment can help in early detection of recurrence and in monitoring how well a patient is responding to treatment. However, the research also indicates that this method is not yet perfect, as it did not detect tumor DNA in all cases. Compared to traditional methods, Circulating DNA Analysis offers a less invasive way to gather information about the tumor, which could lead to quicker treatment decisions and potentially better outcomes for patients.12345
What safety data exists for circulating DNA analysis in soft tissue sarcoma treatment?
The research does not directly address safety data for circulating DNA analysis in soft tissue sarcoma treatment. However, it highlights the potential of liquid biopsy as a minimally invasive method to monitor tumor genetics and disease state, which could reduce the need for invasive tissue biopsies. The studies suggest that while liquid biopsy methods, including circulating tumor DNA analysis, are promising, there are technical challenges and limitations, such as poor concordance with solid tumor genomic profiling, that need to be addressed before widespread clinical implementation. No specific safety concerns are mentioned in the provided abstracts.13467
Is circulating DNA analysis a promising treatment for soft tissue sarcoma?
Yes, circulating DNA analysis is promising for soft tissue sarcoma because it can help detect tumors early, monitor treatment response, and identify recurrences before they are visible on scans. This could lead to earlier and more effective treatment decisions, potentially improving patient survival.12589
Research Team
Albiruni Razak, MD
Principal Investigator
Princess Margaret Cancer Centre
Eligibility Criteria
This trial is for adults over 18 with high-risk soft tissue sarcoma who are suitable for surgery and radiotherapy. They must have a performance status indicating they can care for themselves, have tumor tissue from a biopsy, and be able to consent to the study. Those with other recent cancers, metastases, serious illnesses affecting compliance or planned chemotherapy are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Sample Collection
Blood and tumor tissue samples are collected for DNA testing
Post-Surgery Monitoring
Blood samples are collected 2-4 weeks after cancer surgery
Long-term Follow-up
Blood samples are collected every 12 weeks after surgery for up to 2 years to monitor ctDNA levels
Treatment Details
Interventions
- Archival tumor tissue collection and blood draws
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Mount Sinai Hospital, Canada
Collaborator
The Hospital for Sick Children
Collaborator